Clinical Trial: Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title:

Brief Summary: The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Detailed Summary: This study is an open-label pilot study. Participants will be treated with oral tofacitinib for 3 months. Participants will be evaluated for 6 months after completion of therapy to evaluate for durability of response, late response and/or late adverse effects.
Sponsor: Stanford University

Current Primary Outcome: Mean Change in Severity of Alopecia Tool (SALT) Score [ Time Frame: 0 and 3 months ]

SALT score range is from 0 (no hair loss) to 100 (100% hair loss)


Original Primary Outcome:

  • Mean Change in Severity of Alopecia Tool (SALT) Score [ Time Frame: 3 months ]
    SALT score range is from 0 (no hair loss) to 100 (100% hair loss)
  • Mean Change in Skindex 16 Scores [ Time Frame: 3 months ]
    Skindex 16 is a quality of life questionaire with a range of 0-100 wherein 1 is not bothered by the condition and 100 is always bothered by the condition


Current Secondary Outcome:

Original Secondary Outcome:

Information By: Stanford University

Dates:
Date Received: December 5, 2014
Date Started: December 2014
Date Completion: December 2017
Last Updated: August 7, 2016
Last Verified: August 2016